Announcements Trials

Browse Landscape

Phase

Phase 1 7 Phase 2 4 Phase 1/2 4 Phase 4 1 Phase 3 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Burkitt Lymphoma 1

Interventions

Cisplatin 14 Carboplatin 12 Magnetic Resonance Spectroscopy 11 Specimen Handling 10 Gemcitabine 10 pembrolizumab 8 Pemetrexed 8 atezolizumab 7 Paclitaxel 7 Radiotherapy, Intensity-Modulated 5 Platinum 5 Nivolumab 5 Immunoglobulin G 5 Doxorubicin 5 Docetaxel 5 Disulfides 5 Bevacizumab 5 130-nm albumin-bound paclitaxel 5 1,2-diaminocyclohexaneplatinum II citrate 5 Cetuximab 4 Biopsy 4 durvalumab 3 Temozolomide 3 Standard of Care 3 Rituximab 3 Drug Therapy 3 Dexamethasone 3 Cyclophosphamide 3 (225)Ac-DOTA-c(RGDyK) 3 venetoclax 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × tocilizumab × 30 days × Clear all

NCT07570173 2026-06-05

MK-1045-005

Merck Sharp & Dohme LLC

Phase 2/3 Recruiting

Burkitt Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡